Cambridge-based DIOSynVax and Singapore’s ACM Biolabs are collaborating to develop a next-generation universal bird flu vaccine, featuring potential mucosal delivery to enhance pandemic preparedness.
Key Takeaways
- The mRNA bird flu vaccine development project will use DIOSynVax's AI-enabled antigen design platform and ACM Biolab's delivery platform.
This bilateral project is supported by Innovate UK and Enterprise Singapore, as part of the UK-Singapore Collaborative R&D Call.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?